AU2001257577A1 - Water-soluble polymer conjugates of artelinic acid - Google Patents
Water-soluble polymer conjugates of artelinic acidInfo
- Publication number
- AU2001257577A1 AU2001257577A1 AU2001257577A AU5757701A AU2001257577A1 AU 2001257577 A1 AU2001257577 A1 AU 2001257577A1 AU 2001257577 A AU2001257577 A AU 2001257577A AU 5757701 A AU5757701 A AU 5757701A AU 2001257577 A1 AU2001257577 A1 AU 2001257577A1
- Authority
- AU
- Australia
- Prior art keywords
- water
- soluble polymer
- polymer conjugates
- artelinic acid
- artelinic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- UVNHKOOJXSALHN-ILQPJIFQSA-N artelinic acid Chemical compound O([C@@H]1[C@H](C)[C@@H]2CC[C@H]([C@@H]3CC[C@]4(C)O[C@H]([C@]23OO4)O1)C)CC1=CC=C(C(O)=O)C=C1 UVNHKOOJXSALHN-ILQPJIFQSA-N 0.000 title 1
- 229920003169 water-soluble polymer Polymers 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Polyethers (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18554400P | 2000-02-28 | 2000-02-28 | |
| US60185544 | 2000-02-28 | ||
| PCT/US2001/040190 WO2001062299A2 (en) | 2000-02-28 | 2001-02-26 | Water-soluble polymer conjugates of artelinic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001257577A1 true AU2001257577A1 (en) | 2001-09-03 |
Family
ID=22681435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001257577A Abandoned AU2001257577A1 (en) | 2000-02-28 | 2001-02-26 | Water-soluble polymer conjugates of artelinic acid |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US6461603B2 (en) |
| AU (1) | AU2001257577A1 (en) |
| WO (1) | WO2001062299A2 (en) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2939696T1 (en) | 2001-10-18 | 2016-06-30 | Nektar Therapeutics | Polymer conjugates of opioid antagonists |
| GB0129215D0 (en) * | 2001-12-06 | 2002-01-23 | Ufc Ltd | Trioxane derivatives |
| CA2469224A1 (en) * | 2001-12-06 | 2003-06-12 | Ufc Limited | Trioxane derivatives |
| US20050070595A1 (en) * | 2001-12-06 | 2005-03-31 | O'neil Paul Michael | Trioxane derivatives as antimalaria or anticancer compounds |
| US20060051315A1 (en) * | 2002-02-01 | 2006-03-09 | Scaria Puthupparampil V | Polymers for delivering peptides and small molecules in vivo |
| US6951846B2 (en) | 2002-03-07 | 2005-10-04 | The United States Of America As Represented By The Secretary Of The Army | Artemisinins with improved stability and bioavailability for therapeutic drug development and application |
| US20030171424A1 (en) * | 2002-03-07 | 2003-09-11 | Lin Ai J. | Intravenous formulation of artelinic acid for treatment of severe and complicated malaria |
| US7482376B2 (en) | 2003-07-03 | 2009-01-27 | 3-Dimensional Pharmaceuticals, Inc. | Conjugated complement cascade inhibitors |
| BRPI0414017B8 (en) * | 2003-09-17 | 2021-05-25 | Nektar Therapeutics Al Corp | multi-arm polymeric prodrug, pharmaceutical composition and method for preparing a multi-arm polymeric prodrug. |
| US8394365B2 (en) | 2003-09-17 | 2013-03-12 | Nektar Therapeutics | Multi-arm polymer prodrugs |
| US20060182692A1 (en) | 2003-12-16 | 2006-08-17 | Fishburn C S | Chemically modified small molecules |
| SI1694363T1 (en) * | 2003-12-16 | 2014-03-31 | Nektar Therapeutics | Monodisperse PEGylated naloxol compositions |
| US8906676B2 (en) | 2004-02-02 | 2014-12-09 | Ambrx, Inc. | Modified human four helical bundle polypeptides and their uses |
| WO2006069220A2 (en) | 2004-12-22 | 2006-06-29 | Ambrx, Inc. | Modified human growth hormone |
| AU2005265163B2 (en) | 2004-06-18 | 2009-10-01 | Ambrx, Inc. | Novel antigen-binding polypeptides and their uses |
| WO2006019904A1 (en) | 2004-07-14 | 2006-02-23 | University Of Utha Research Foundation | Netrin-related compositions and uses |
| WO2006091231A2 (en) | 2004-07-21 | 2006-08-31 | Ambrx, Inc. | Biosynthetic polypeptides utilizing non-naturally encoded amino acids |
| NZ555386A (en) | 2004-12-22 | 2011-01-28 | Ambrx Inc | Formulations of human growth hormone comprising a non-naturally encoded amino acid |
| CN103290084A (en) | 2004-12-22 | 2013-09-11 | Ambrx公司 | Method for expression and purification of recombinant human growth hormone |
| CA2590429C (en) | 2004-12-22 | 2014-10-07 | Ambrx, Inc. | Compositions of aminoacyl-trna synthetase and uses thereof |
| US8273339B2 (en) | 2005-04-12 | 2012-09-25 | Nektar Therapeutics | Polymer-based compositions and conjugates of antimicrobial agents |
| EP1893229B1 (en) | 2005-06-03 | 2011-10-19 | Ambrx, Inc. | Improved human interferon molecules and their uses |
| BRPI0612407A2 (en) * | 2005-07-08 | 2010-11-03 | Elan Pharm Inc | preparation of polymeric conjugates of therapeutic compounds, agricultural compounds and food additives |
| WO2007021297A1 (en) | 2005-08-18 | 2007-02-22 | Ambrx, Inc. | COMPOSITIONS OF tRNA AND USES THEREOF |
| WO2007059312A2 (en) | 2005-11-16 | 2007-05-24 | Ambrx, Inc. | Methods and compositions comprising non-natural amino acids |
| US7671067B2 (en) * | 2006-02-09 | 2010-03-02 | Enzon Pharmaceuticals, Inc. | Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin |
| US7462627B2 (en) * | 2006-02-09 | 2008-12-09 | Enzon Pharmaceuticals, Inc. | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
| CN101437850B (en) | 2006-03-10 | 2013-10-09 | 惠氏公司 | Anti-5T4 antibodies and uses thereof |
| CA2662753C (en) | 2006-09-08 | 2016-02-23 | Ambrx, Inc. | Hybrid suppressor trna for vertebrate cells |
| JP5451390B2 (en) | 2006-09-08 | 2014-03-26 | アンブルックス，インコーポレイテッド | Transcription of suppressor TRNA in vertebrate cells |
| EP2069396B1 (en) | 2006-09-08 | 2015-10-21 | Ambrx, Inc. | Modified human plasma polypeptide or fc scaffolds and their uses |
| KR101441709B1 (en) | 2006-11-30 | 2014-09-18 | 넥타르 테라퓨틱스 | METHOD FOR PRODUCING POLYMER CONJUGATE |
| US7566465B2 (en) * | 2006-12-21 | 2009-07-28 | The United States Of America As Represented By The Secretary Of The Army | Artemisinins in the clinical and veterinary management of kinetoplastid infections |
| MX2009008549A (en) * | 2007-02-09 | 2009-08-18 | Enzon Pharmaceuticals Inc | Treatment of resistant or refractory cancers with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin. |
| US8012931B2 (en) | 2007-03-30 | 2011-09-06 | Ambrx, Inc. | Modified FGF-21 polypeptides and their uses |
| AU2008247815B2 (en) | 2007-05-02 | 2012-09-06 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
| MX338336B (en) | 2007-11-20 | 2016-04-07 | Ambrx Inc | Modified insulin polypeptides and their uses. |
| EP2247743B1 (en) | 2008-02-08 | 2016-04-06 | Ambrx, Inc. | Modified leptin polypeptides and their uses |
| ES2963062T3 (en) | 2008-07-23 | 2024-03-25 | Ambrx Inc | Modified bovine G-CSF polypeptides and their uses |
| KR101671537B1 (en) | 2008-08-11 | 2016-11-01 | 넥타르 테라퓨틱스 | Multi-arm polymeric alkanoate Conjugates |
| US20100056555A1 (en) * | 2008-08-29 | 2010-03-04 | Enzon Pharmaceuticals, Inc. | Method of treating ras associated cancer |
| HRP20192120T1 (en) | 2008-09-23 | 2020-02-21 | Nektar Therapeutics | Method of metronomic dosing with camptotecin prodrugs (e.g. pec-irinotecan) |
| TR201802361T4 (en) | 2008-09-26 | 2018-03-21 | Ambrx Inc | Microorganisms and vaccines dependent on unnatural amino acid replication. |
| EA019653B1 (en) | 2008-09-26 | 2014-05-30 | Амбркс Инк. | Modified animal erythropoietin polypeptides and their uses |
| EP2341774B1 (en) * | 2008-10-21 | 2013-12-04 | Belrose Pharma Inc. | Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin |
| US20120283172A1 (en) | 2009-12-21 | 2012-11-08 | Ambrx, Inc. | Modified porcine somatotropin polypeptides and their uses |
| CA2784793A1 (en) | 2009-12-21 | 2011-07-21 | Ambrx, Inc. | Modified bovine somatotropin polypeptides and their uses |
| MX346786B (en) | 2010-08-17 | 2017-03-31 | Ambrx Inc | Modified relaxin polypeptides and their uses. |
| US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
| TWI480288B (en) | 2010-09-23 | 2015-04-11 | Lilly Co Eli | Formulations for bovine granulocyte colony stimulating factor and variants thereof |
| PH12013500561A1 (en) | 2010-09-30 | 2013-06-10 | Astrazeneca Ab | Crystalline naloxol-peg conjugate |
| WO2012083197A1 (en) | 2010-12-17 | 2012-06-21 | Nektar Therapeutics | Water-soluble polymer conjugates of topotecan |
| EP2654795B1 (en) | 2010-12-21 | 2018-03-07 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds |
| US10894087B2 (en) | 2010-12-22 | 2021-01-19 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds |
| US20130331443A1 (en) | 2010-12-22 | 2013-12-12 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of taxane-based compounds |
| AU2012296950B2 (en) | 2011-08-12 | 2016-09-22 | Ascendis Pharma A/S | Polymeric hyperbranched carrier-linked prodrugs |
| CA2843875C (en) | 2011-08-12 | 2020-01-07 | Ascendis Pharma A/S | High-loading water-soluble carrier-linked prodrugs |
| US9358261B2 (en) | 2011-10-25 | 2016-06-07 | U.S. Phytotherapy, Inc. | Additional artemisinin and berberine compositions and methods of making |
| US9675582B2 (en) | 2011-10-25 | 2017-06-13 | U.S. Phytotherapy, Inc. | Alternative ACT with natural botanical active GRAS ingredients for treatment and prevention of the Zika virus |
| CA2853701A1 (en) | 2011-10-25 | 2013-05-02 | U.S. Phytotherapy, Inc. | Artemisinin and berberine compositions and methods of making |
| JP2015502397A (en) | 2011-12-23 | 2015-01-22 | ファイザー・インク | Engineered antibody constant regions for site-specific conjugation, and methods and uses therefor |
| US10118996B2 (en) * | 2012-02-24 | 2018-11-06 | Purdue Research Foundation | Polyrotaxanes and uses thereof |
| BR112014030278A2 (en) | 2012-06-08 | 2017-06-27 | Sutro Biopharma Inc | antibody and composition. |
| EP2863955B1 (en) | 2012-06-26 | 2016-11-23 | Sutro Biopharma, Inc. | Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use |
| DK2890402T3 (en) | 2012-08-31 | 2019-07-15 | Sutro Biopharma Inc | MODIFIED AMINO ACIDS INCLUDING AN AZIDOG GROUP |
| CN104208715B (en) * | 2013-05-31 | 2016-12-28 | 天津键凯科技有限公司 | There is the medicine bioactive low molecular poly drug conjugates of raising |
| WO2015006555A2 (en) | 2013-07-10 | 2015-01-15 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| WO2015041722A1 (en) | 2013-09-17 | 2015-03-26 | Kryptonite Group, Ltd | Enhanced artemisinin-based combination therapy for treating parasitic mediated disease |
| US9840493B2 (en) | 2013-10-11 | 2017-12-12 | Sutro Biopharma, Inc. | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use |
| TW201605480A (en) | 2013-11-04 | 2016-02-16 | 輝瑞大藥廠 | Anti-EFNA4 antibody-drug conjugates |
| ES2856927T3 (en) | 2014-04-30 | 2021-09-28 | Pfizer | Anti-PTK7 Drug-Antibody Conjugates |
| US10479854B2 (en) * | 2014-08-12 | 2019-11-19 | Stellenbosch University | Conjugate for treating malaria |
| EP3909596A1 (en) | 2014-10-24 | 2021-11-17 | Bristol-Myers Squibb Company | Modified fgf-21 polypeptides and uses thereof |
| TWI727380B (en) | 2015-11-30 | 2021-05-11 | 美商輝瑞股份有限公司 | Site specific her2 antibody drug conjugates |
| TWI812873B (en) | 2015-11-30 | 2023-08-21 | 美商輝瑞股份有限公司 | Antibodies and antibody fragments for site-specific conjugation |
| MY193457A (en) | 2017-02-08 | 2022-10-14 | Bristol Myers Squibb Co | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
| US11364303B2 (en) | 2017-09-29 | 2022-06-21 | Pfizer Inc. | Cysteine engineered antibody drug conjugates |
| PL3849614T3 (en) | 2018-09-11 | 2024-04-22 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and their uses |
| US20220009986A1 (en) | 2018-10-19 | 2022-01-13 | Ambrx, Inc. | Interleukin-10 polypeptide conjugates, dimers thereof, and their uses |
| NZ778565A (en) | 2019-02-12 | 2025-10-31 | Ambrx Inc | Compositions containing, methods and uses of antibody-tlr agonist conjugates |
| EP4117732A1 (en) | 2020-03-11 | 2023-01-18 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and methods of use thereof |
| WO2022040596A1 (en) | 2020-08-20 | 2022-02-24 | Ambrx, Inc. | Antibody-tlr agonist conjugates, methods and uses thereof |
| CA3213805A1 (en) | 2021-04-03 | 2022-10-06 | Feng Tian | Anti-her2 antibody-drug conjugates and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4791135A (en) * | 1987-08-20 | 1988-12-13 | The United States Of America As Represented By The Secretary Of The Army | Novel antimalarial dihydroartemisinin derivatives |
| AU4406793A (en) * | 1992-06-04 | 1993-12-30 | Clover Consolidated, Limited | Water-soluble polymeric carriers for drug delivery |
| US5840900A (en) | 1993-10-20 | 1998-11-24 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5677468A (en) | 1995-06-29 | 1997-10-14 | Hauser, Inc. | Artemisinin dimer compounds having anticancer activity |
| US5840925A (en) | 1995-06-29 | 1998-11-24 | Hauser, Inc. | Trioxane dimer compounds having antiproliferative and antitumor activities |
| US6004997A (en) | 1995-06-29 | 1999-12-21 | Hauser, Inc. | Trioxane dimer compounds having antiproliferative and antitumor activities |
| JP4193917B2 (en) | 1995-12-18 | 2008-12-10 | アンジオデバイス インターナショナル ゲーエムベーハー | Crosslinked polymer composition and method of use thereof |
| US5830986A (en) | 1996-10-28 | 1998-11-03 | Massachusetts Institute Of Technology | Methods for the synthesis of functionalizable poly(ethylene oxide) star macromolecules |
| US6156790A (en) | 1997-12-30 | 2000-12-05 | Hauser, Inc. | C-10 carbon-substituted artemisinin-like trioxane compounds having antimalarial, antiproliferative and antitumor activities |
| US6160004A (en) | 1997-12-30 | 2000-12-12 | Hauser, Inc. | C-10 carbon-substituted artemisinin-like trioxane compounds having antimalarial, antiproliferative and antitumor activities |
-
2001
- 2001-02-26 WO PCT/US2001/040190 patent/WO2001062299A2/en not_active Ceased
- 2001-02-26 AU AU2001257577A patent/AU2001257577A1/en not_active Abandoned
- 2001-02-27 US US09/794,731 patent/US6461603B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001062299A2 (en) | 2001-08-30 |
| US20010041172A1 (en) | 2001-11-15 |
| US6461603B2 (en) | 2002-10-08 |
| WO2001062299A3 (en) | 2002-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001257577A1 (en) | Water-soluble polymer conjugates of artelinic acid | |
| HUP0204544A3 (en) | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates | |
| AU2002235126A1 (en) | Novel polyamine analog-amino acid conjugates useful as anticancer agents | |
| AU2002225855A1 (en) | Preparation of nanocrystallites | |
| AU5935300A (en) | Fluorescent water-soluble polymers | |
| AU2002217981A1 (en) | Water-soluble polymer conjugates of triazine derivatives | |
| AU2001240026A1 (en) | Camptothecin conjugates | |
| AU2001259472A1 (en) | Aqueous adhesive formulations | |
| AU2001265111A1 (en) | Benzenedicarboxylic acid derivatives | |
| AU2001280598A1 (en) | Anti-occlusion catheter | |
| AU2001222986A1 (en) | Dehydroascorbic acid formulations and uses thereof | |
| AU2001280167A1 (en) | Novel propenohydroxamic acid derivatives | |
| AU2002214324A1 (en) | Medicinal compositions | |
| AU2001290239A1 (en) | Medicinal composition | |
| AU2001276749A1 (en) | Polymer composition | |
| AU2001289635A1 (en) | Polymeric conjugates of antitumor agents | |
| AU2002214978A1 (en) | Beta-Thio-amino acids | |
| AU2002350942A1 (en) | Imidazolidineacetic acid derivatives | |
| AU2882601A (en) | Connector | |
| AUPR218000A0 (en) | Polymer gels and their preparation | |
| AU2001291691A1 (en) | Drugs for incontinence | |
| AU2002229469A1 (en) | Connector | |
| AU2001282527A1 (en) | Antiparkinsonism drugs | |
| AU2001240543A1 (en) | Cytostatic agent glycoconjugate | |
| AUPQ851000A0 (en) | Rapid fatty acid delivery |